Fig. 5
From: Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways
TAZS89A induces liver cancer in collaboration with either BRAFV600E or PI3KE545K. A Schematic illustration of the experimental procedure. B Gross morphology of representative livers expressing EGFP (control), BRAFV600E, and PI3KE545K, respectively, together with TAZS89A. Livers were harvested at 6 weeks following the hydrodynamic injection (n = 5 mice per group)